ARTICLE | Finance

Regulatory milestones

February 1, 2010 8:00 AM UTC

Amsterdam Molecular Therapeutics (Euronext:AMT) lost €0.08 to €3.37 last week after the EMA accepted for filing an MAA for Glybera (AMT-011) to treat lipoprotein lipase (LPL) deficiency.

Theratechnologies Inc. (TSX:TH) was off C$0.43 to C$4.64 last week on news FDA will reschedule a Feb. 24 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to discuss an NDA for tesamorelin, an analog of growth hormone releasing factor to treat excess abdominal fat in HIV patients with lipodystrophy (see B9)...